Prognostic Value of p53 and Ki-67 Expression in Intermediate-risk Patients With Nonmuscle-invasive Bladder Cancer Receiving Adjuvant Intravesical Mitomycin C Therapy

These results suggest that Ki-67 expression can identify a subset of intermediate-risk patients with nonmuscle-invasive bladder cancer in whom intravesical mitomycin C therapy could be effective.